

RECEIVED  
CENTRAL FAX CENTER

MAR 28 2005

NEEDLE &amp; ROSENBERG

## IMPORTANT FAX DOCUMENT

NEEDLE & ROSENBERG PC  
SUITE 1000  
999 PEACHTREE STREET  
ATLANTA, GEORGIA 30309-3915  
678-420-9300  
NEEDLEROSENBERG.COM

Date: March 28, 2005

Name: Examiner Nashaat T. Nashed

Company: United States Patent and Trademark Office

Your Reference: Application Serial No. 09/884,260

Fax Number: 703 872-9306

From: Christopher L. Gurfman, J.D., Ph.D.

Our Reference No: 06027.0002U2

Our Fax Number: 678-420-9301

No. of Pages: 9

## Comments:

Per the attached Response to Final Office Action.

## CONFIDENTIALITY NOTE

*The information which follows and is transmitted herewith is attorney privileged, trade secret and confidential information intended only for viewing and use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any review, use, communication, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone and return the original message to us at the above address.*

**ATTORNEY DOCKET NO.: 06027.0002U2  
PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****RECEIVED  
CENTRAL FAX CENTER**

In re application of )

BRASH et al. )

Application No.: 09/884,260 )

Filed: June 19, 2001 )

For: MUSKMELON (*CUCUMIS MELO*) )  
HYDROPEROXIDE LYASE AND )  
USES THEREOF )

Group Art Unit: 1652

Examiner: Nashed, Nashaat T.

Confirmation No.: 3583

MAR 28 2005

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
ATTN: Examiner Nashaat T. Nashed  
Fax No. (703) 872-9306NEEDLE & ROSENBERG, P.C.  
Customer Number 23859

March 28, 2005

**RESPONSE TO FINAL OFFICE ACTION**

Sir:

This paper is in response to the Final Office Action dated January 26, 2005. Please amend the above-identified application as set forth below and consider the Remarks that follow.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 7 of this paper.